It is good industry practice to clarify the precise remit for each of the reviewers of a controlled document, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.
Q. In a recent audit, we were asked about the meaning of the signatures on our controlled documents. Our reply was that it clearly states that the signatories are either authors, reviewers, or approvers. The auditor considered our response insufficient, pointing out that we often have up to 10 reviewers. Though the names and titles of these are given, their review responsibilities are not defined or described. We are unclear how to make the meaning of the signatures more precise.
A. The regulations do not provide much detail with regards to your question. For example, the European Union guidelines (1) require, “Documents containing instructions should be approved, signed, and dated by appropriate and authorised persons.” The US regulations are a little bit more specific in 21 Code of Federal Regulations (CFR) Part 11 (2) regarding the signing of electronic records and state, “This information must include the printed name of the signer, the date and time when the signature was executed, and the meaning [emphasis added] (such as review, approval, responsibility, and authorship) associated with the signature.”
The question is whether the meaning of the signatures in your documents is clear enough and unambiguous. Let us look at an example, such as a cleaning standard operating procedure (SOP) for manufacturing equipment. An author, most likely a member of the operations team, prepares the document. There will be several reviewers, possibly including manufacturing, engineering, validation, quality unit, regulatory affairs, and health and safety. These reviewers will each have a different perspective from which they perform their review.
One could argue that the role and the associated job description define sufficiently what a reviewer has to do. In theory, yes; but in practice this is often not the case. Therefore, companies typically apply one of two approaches: either define the controlled documents review and approval responsibilities in a document (e.g., the SOP for SOPs) or add the meaning to each signature in the signature list.
Table I is an example of such a review responsibilities matrix.
If we apply this to the cleaning SOP example, we would expect:
In summary, it is good industry practice to clarify the precise remit for each of the reviewers of a controlled document, rather than just apply the general term of ‘reviewer.’ This does not have to be as difficult as the example herein.
And finally: are you still sure you need up to 10 reviewers?
1. European Commission, EudraLex Vol. 4 Part I Chapter 4 Documentation.
2. Electronic Records; Electronic Signatures, Federal Register 62 (54), March 20, 1997.
BioPharm International
Vol. 32, No. 11
November 2019
Page: 54-53
When referring to this article, please cite it as S. Schmitt, "Signatures–What’s in a Name?," BioPharm International 32 (11) 2019.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.